IP Library Granted Patent US 8,753,665
Granted Patent B2
US 8,753,665 · App. 11/663,125 · Granted Jun 17, 2014

Controlled delivery system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,753,665
App. No.
11/663,125
Granted
Jun 17, 2014
Kind
B2
Abstract

The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. Preferably the composition contains bupivacaine and a sugar ester such as saib.

Claims (42)

1. A composition comprising:

20% to 10% by weight bupivacaine free base relative to the total weight of the composition;

about 75% to about 25% by weight sucrose acetate isobutyrate (SAIB) relative to the total weight of the composition; and about 55% to about 10% by weight benzyl alcohol relative to the total weight of the composition; wherein upon administration to a subject, bupivacaine is released from the composition in an amount sufficient to provide a local anesthetic effect at a site of administration for at least 24 hours after administration.

2. A method for providing sustained local anesthesia to a subject, said method comprising administering to the subject the composition of claim 1 .

3. The method of claim 2 , wherein said administering is by topical application.

4. The method of claim 2 , wherein said administering is by injection.

5. The method of claim 2 , wherein said administering comprises administering as an implant.

6. The method of claim 2 , wherein the site is a surgical wound.

7. The method of claim 2 , wherein the composition is administered in or adjacent a surgical wound.

8. The composition of claim 1 , wherein said composition is suitable for topical, systemic, or parenteral administration.

9. The composition of claim 1 , wherein said composition is suitable for administration via injection, pouring, spraying, dipping, aerosolizing, or via a coating applicator.

10. The method of claim 2 , wherein said composition is administered by pouring.

11. The method of claim 2 , wherein said subject is a human patient undergoing surgical inguinal hernia repair or an appendectomy.

12. The method of claim 2 , wherein said composition is used to treat post-operative pain.

13. The method of claim 2 , wherein less than about 20% of the bupivacaine present in the composition is released within 24 hours after administration.

14. The composition of claim 1 , wherein the SAIB and the benzyl alcohol form a low viscosity liquid carrier material having a viscosity ranging from 200 cP to 6000 cP.

15. The composition of claim 1 , wherein the composition does not comprise a polymer.

16. The method of claim 2 , wherein the administering does not comprise injection.

17. The composition of claim 1 , wherein the composition provides the local anesthetic effect up to 4 days after administration.

18. A composition comprising:

20% to 10% by weight bupivacaine free base relative to the total weight of the composition;

sucrose acetate isobutyrate (SAIB) present in an amount of from about 75% to about 25% by weight relative to the total weight of the composition; and

benzyl alcohol present in an amount of from about 50% to about 15% by weight relative to the total weight of the composition,

wherein upon administration to a subject, bupivacaine is released from the composition in an amount sufficient to provide a local anesthetic effect at a site of administration for at least 24 hours after administration.

19. The composition of claim 18 , wherein the composition provides the local anesthetic effect for at least 36 hours after administration.

20. The composition of claim 19 , wherein the composition provides the local anesthetic effect for at least 48 hours after administration.

21. The composition of claim 18 , wherein said composition is suitable for topical, systemic, or parenteral administration.

22. The composition of claim 18 , wherein said composition is suitable for administration via injection, pouring, spraying, dipping, aerosolizing, or via a coating applicator.

23. The composition of claim 18 , wherein the SAIB and the benzyl alcohol form a low viscosity liquid carrier material having a viscosity ranging from 200 cP to 6000 cP.

24. The composition of claim 18 , wherein the composition does not comprise a polymer.

25. The composition of claim 18 , wherein the composition provides the local anesthetic effect up to 4 days after administration.

26. A method for providing sustained local anesthesia to a subject, said method comprising administering to the subject the composition of claim 18 .

27. The method of claim 26 , wherein said administering is by topical application.

28. The method of claim 26 , wherein said administering is by injection.

29. The method of claim 26 , wherein said administering comprises administering as an implant.

30. The method of claim 26 , comprising administering to a surgical wound.

31. The method of claim 26 , wherein the composition is administered in or adjacent a surgical wound.

32. The method of claim 26 , wherein said composition is administered by pouring.

33. The method of claim 26 , wherein said subject is a human patient undergoing surgical inguinal hernia repair or an appendectomy.

34. The method of claim 26 , wherein said composition is used to treat post-operative pain.

35. The method of claim 26 , wherein less than about 20% of the bupivacaine present in the composition is released within 24 hours after administration.

36. The method of claim 26 , wherein the administering does not comprise injection.

Assignments (6)
SECURITY INTEREST Recorded Mar 30, 2026
From: BAUSCH HEALTH IRELAND LIMITED; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 074223/0753 →
SECURITY INTEREST Recorded Mar 30, 2026
From: MEDICIS PHARMACEUTICAL CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 074227/0509 →
MERGER Recorded Feb 25, 2026
From: DURECT CORPORATION
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 073889/0196 →
MERGER Recorded Feb 19, 2026
From: DURECT CORPORATION
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 073837/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: LEE, MIN L.; MIKSZTAL, ANDREW R.
To: DURECT CORPORATION
Reel/Frame 059990/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2007
From: VERITY, ADRIAN NEIL
To: DURECT CORPORATION
Reel/Frame 019231/0011 →